Insider Buying: Harrow (NASDAQ:HROW) Director Purchases 1,000 Shares of Stock

May 20, 2026 by InsiderTrades.com

Key Points

Director Adrienne Graves bought 1,000 shares of Harrow at $31.07 each, totaling $31,070, a modest insider purchase that may signal confidence in the company.
Harrow recently missed quarterly earnings and revenue estimates, reporting EPS of -$0.74 versus expectations of -$0.43 and revenue of $44.2 million versus $52.43 million forecast.
Analyst sentiment remains mixed but generally positive, with a consensus “Moderate Buy” rating and an average price target of $69.43, while HC Wainwright reiterated a Buy rating and $70 target.

Harrow, Inc. (NASDAQ:HROW - Get Free Report) Director Adrienne Graves bought 1,000 shares of the company's stock in a transaction on Monday, May 18th. The shares were acquired at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the acquisition, the director directly owned 1,000 shares of the company's stock, valued at $31,070. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Harrow Trading Down 0.7%

NASDAQ HROW opened at $30.68 on Wednesday. Harrow, Inc. has a one year low of $25.21 and a one year high of $54.85. The company has a 50-day simple moving average of $36.30 and a 200-day simple moving average of $42.07. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.30 and a current ratio of 2.48. The firm has a market capitalization of $1.14 billion, a PE ratio of -74.83 and a beta of 0.34.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The business had revenue of $44.20 million for the quarter, compared to analyst estimates of $52.43 million. During the same quarter last year, the company earned ($0.38) EPS. On average, equities analysts forecast that Harrow, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

HROW has been the subject of a number of analyst reports. Weiss Ratings lowered Harrow from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, April 22nd. Cantor Fitzgerald dropped their target price on Harrow from $91.00 to $88.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. B. Riley Financial reissued a "buy" rating and set a $65.00 price target (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. William Blair restated an "outperform" rating on shares of Harrow in a research report on Tuesday, March 3rd. Finally, Zacks Research raised shares of Harrow from a "strong sell" rating to a "hold" rating in a report on Friday, April 3rd. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Harrow has an average rating of "Moderate Buy" and a consensus price target of $69.43.

Check Out Our Latest Research Report on HROW

More Harrow News

Here are the key news stories impacting Harrow this week:

Positive Sentiment: Director Adrienne L. Graves bought 1,000 shares of Harrow at $31.07 per share, a small but notable insider purchase that can signal confidence in the company’s outlook. SEC filing
Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Harrow, implying meaningful upside from current levels.
Positive Sentiment: The firm raised its Q4 2026 EPS estimate to $0.61 from $0.40, suggesting stronger profitability later in the fiscal year.
Positive Sentiment: HC Wainwright also sees a stronger back half of the forecast period, including $0.40 EPS in Q3 2027, $1.06 in Q4 2027, and $1.14 for FY2027.
Neutral Sentiment: At the same time, HC Wainwright cut its FY2026 EPS estimate to $0.15 from $0.56 and reduced Q2 2026 EPS to $0.01 from $0.10, reflecting near-term earnings pressure.
Neutral Sentiment: The company recently reported a quarterly EPS miss and revenue below expectations, which remains a reminder that execution has been uneven.

Hedge Funds Weigh In On Harrow

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company's stock worth $261,000 after acquiring an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock valued at $483,000 after purchasing an additional 790 shares in the last quarter. Strs Ohio acquired a new stake in Harrow in the first quarter worth about $149,000. Legal & General Group Plc lifted its holdings in Harrow by 12.4% in the second quarter. Legal & General Group Plc now owns 30,753 shares of the company's stock worth $939,000 after purchasing an additional 3,384 shares during the period. Finally, Rhumbline Advisers grew its position in Harrow by 9.3% in the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company's stock valued at $1,434,000 after buying an additional 3,994 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

Harrow Company Profile

(Get Free Report)

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.